Literature DB >> 28499830

Implementation of a systematic culturing program to monitor the efficacy of endoscope reprocessing: outcomes and costs.

Gene K Ma1, David A Pegues2, Michael L Kochman1, Kevin Alby3, Neil O Fishman2, Marianne Saunders4, Carolyn Grous4, Daniel T Dempsey4, Gregory G Ginsberg1.   

Abstract

BACKGROUND AND AIMS: In 2015, the U.S. Food and Drug Administration and Centers for Disease Control and Prevention (CDC) issued guidance for duodenoscope culturing and reprocessing in response to outbreaks of carbapenem-resistant Enterobacteriaceae (CRE) duodenoscope-related infections. Based on this guidance, we implemented best practices for reprocessing and developed a systematic process for culturing endoscopes with elevator levers. The aim of this study is to report the outcomes and direct costs of this program.
METHODS: First, clinical microbiology data from 2011 to 2014 were reviewed retrospectively to assess for possible elevator lever-equipped endoscope-related CRE infections. Second, a program to systematically culture elevator lever-equipped endoscopes was implemented. Each week, about 25% of the inventory of elevator lever-equipped endoscopes is cultured based on the CDC guidelines. If any cultures return bacterial growth, the endoscope is quarantined pending repeat culturing. The costs of the program, including staff time and supplies, have been calculated.
RESULTS: From 2011 to 2014, none of 17 patients with documented CRE infection had undergone ERCP or endoscopic ultrasound in the previous 36 months. From June 2015 to September 2016, 285 cultures were performed. Three (1.1%) had bacterial growth, 2 with skin contaminants and 1 with an oral contaminant. The associated endoscopes were quarantined and reprocessed, and repeat cultures were negative. The total estimated cost of our program for an inventory of 20 elevator lever-equipped endoscopes was $30,429.60 per year ($1521.48 per endoscope).
CONCLUSIONS: This 16-month evaluation of a systematic endoscope culturing program identified a low rate of positive cultures after elevator lever endoscope reprocessing. All positive cultures were with non-enteric microorganisms. The program was of modest cost and identified reprocessing procedures that may have led to a low rate of positive cultures.
Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28499830     DOI: 10.1016/j.gie.2017.05.001

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  5 in total

1.  Eliminating Duodenoscope-Associated Transmission of Carbapenem-Resistant Enterobacteriaceae (CRE): In Search of an Optimal Strategy.

Authors:  Divyanshoo R Kohli; Thomas E Grys; Rahul Pannala
Journal:  Dig Dis Sci       Date:  2017-11       Impact factor: 3.199

2.  Turbulent fluid flow is a novel closed-system sample extraction method for flexible endoscope channels of various inner diameters.

Authors:  Seo Yean Sohn; Michelle J Alfa; Richard Lai; Yacoob Tabani; Mohamed E Labib
Journal:  J Microbiol Methods       Date:  2019-11-20       Impact factor: 2.363

3.  Evaluation of an overnight non-culture test for detection of viable Gram-negative bacteria in endoscope channels.

Authors:  Harminder Singh; Donald R Duerksen; Gale Schultz; Carol Reidy; Pat DeGagne; Nancy Olson; Zoann Nugent; Michelle J Alfa
Journal:  Endosc Int Open       Date:  2019-01-30

4.  A Prospective, Randomized Comparison of Duodenoscope Reprocessing Surveillance Methods.

Authors:  Travis J De Wolfe; Nasia Safdar; Megan Meller; John Marx; Patrick R Pfau; Eric M Nelsen; Mark E Benson; Anurag Soni; Mark Reichelderfer; Megan Duster; Deepak V Gopal
Journal:  Can J Gastroenterol Hepatol       Date:  2019-11-18

Review 5.  A narrative review on current duodenoscope reprocessing techniques and novel developments.

Authors:  Maarten Heuvelmans; Herman F Wunderink; Henny C van der Mei; Jan F Monkelbaan
Journal:  Antimicrob Resist Infect Control       Date:  2021-12-23       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.